Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
Jamie N. Justice(Wake Forest University), James L. Kirkland(Cedars-Sinai Medical Center), Nicolas Musi(Cedars-Sinai Medical Center), Tamar Tchkonia(Cedars-Sinai Medical Center), Anoop M. Nambiar(The University of Texas at San Antonio Health Science Center), Larissa Prata(Cedars-Sinai Medical Center), Michał M. Masternak(University of Central Florida), Stephen B. Kritchevsky(Wake Forest University), Shahrukh Hashmi(Abu Dhabi Health Services), Rodolfo M. Pascual(Atrium Health Wake Forest Baptist), Nathan K. LeBrasseur(WinnMed)
Cited by 1,180
Related Papers
The Loss of Skeletal Muscle Strength, Mass, and Quality in Older Adults: The Health, Aging and Body Composition Study
|The Journals of Gerontology Series A|2006|3k
The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final Estimates
|The Journals of Gerontology Series A|2014|2.5k
The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs
|Aging Cell|2015|2.4k
Strength, But Not Muscle Mass, Is Associated With Mortality in the Health, Aging and Body Composition Study Cohort
|The Journals of Gerontology Series A|2006|1.7k
Cellular senescence mediates fibrotic pulmonary disease
|Nature Communications|2017|1.5k